Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by ING Groep NV

ING Groep NV cut its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 5.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 6,531 shares of the medical research company’s stock after selling 374 shares during the period. ING Groep NV’s holdings in Charles River Laboratories International were worth $1,206,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Versant Capital Management Inc grew its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 150 shares during the period. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after buying an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. lifted its stake in shares of Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after buying an additional 65 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the 3rd quarter worth approximately $59,000. Finally, ORG Wealth Partners LLC acquired a new position in Charles River Laboratories International during the fourth quarter worth $56,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CRL. Morgan Stanley cut their price objective on shares of Charles River Laboratories International from $220.00 to $184.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 5th. JPMorgan Chase & Co. dropped their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating for the company in a report on Thursday. Bank of America cut their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, Barclays cut their target price on shares of Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 18th. Three equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $195.71.

Charles River Laboratories International Price Performance

Charles River Laboratories International stock opened at $163.11 on Monday. The company has a current ratio of 1.41, a quick ratio of 1.14 and a debt-to-equity ratio of 0.65. The company has a fifty day simple moving average of $172.84 and a 200-day simple moving average of $188.00. The stock has a market cap of $8.34 billion, a P/E ratio of 1,087.39, a price-to-earnings-growth ratio of 4.54 and a beta of 1.37. Charles River Laboratories International, Inc. has a 12-month low of $150.79 and a 12-month high of $275.00.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the previous year, the business earned $2.46 EPS. Charles River Laboratories International’s revenue for the quarter was down 1.1% on a year-over-year basis. Equities analysts expect that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Activity at Charles River Laboratories International

In related news, EVP Joseph W. Laplume sold 4,400 shares of the company’s stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the sale, the executive vice president now owns 20,013 shares in the company, valued at $3,252,112.50. This represents a 18.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Birgit Girshick bought 1,514 shares of the firm’s stock in a transaction dated Thursday, February 20th. The shares were acquired at an average price of $164.63 per share, with a total value of $249,249.82. Following the purchase, the chief operating officer now directly owns 55,058 shares of the company’s stock, valued at approximately $9,064,198.54. This trade represents a 2.83 % increase in their position. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).